Jennifer Pietenpol

Authors on the study included, from left, Jennifer Pietenpol, PhD, Melinda Sanders, MD, Brian Lehmann, PhD, Vandana Abramson, MD, and Yu Shyr, PhD. (photo by Donn Jones)
December 15, 2023

Clinical trial shows efficacy for atezolizumab combined with carboplatin

By Tom Wilemon
March 22, 2022

VUMC’s Pietenpol, Shyr named AACR Fellows

Vanderbilt’s Jennifer Pietenpol, PhD, and Yu Shyr, PhD, have been inducted as fellows of the American Association for Cancer Research Academy.

By Tom Wilemon
February 10, 2022

Pietenpol named chief scientific and strategy officer

Jennifer Pietenpol, PhD, director of the Vanderbilt-Ingram Cancer Center (VICC), Benjamin F. Byrd Jr. Professor of Oncology and Executive Vice President for Research for Vanderbilt University Medical Center, is stepping down on June 30 from her long-held role as the Cancer Center’s director to focus on a combined leadership role for VUMC as chief scientific and strategy officer (CSSO).

By John Howser
November 18, 2021

‘Multi-omics’ reveals treatment option for breast cancer subtype

By Bill Snyder
The team studying tumor suppressor protein p53 includes, from left, Jennifer Pietenpol, PhD, and Lindsay Redman-Rivera.
September 2, 2021

Discovery offers insight for development of cancer therapies targeting mutant p53

Vanderbilt researchers have discovered that aneuploidy (an abnormal number of chromosomes) drives malignant phenotypes in cells expressing mutant p53, a tumor suppressor protein that is mutated in more than half of all human cancers.

By Bill Snyder
August 19, 2021

Expression atlas for cell regulators

Vanderbilt researchers report a comprehensive tissue-specific atlas of protein and mRNA expression for p63 and p73, members of the p53 family signaling network that is the most frequent target of mutations in human cancers.

By Leigh MacMillan
September 29, 2020

VICC receives ‘exceptional’ score with renewal as an NCI-Designated Comprehensive Cancer Center

Vanderbilt-Ingram Cancer Center (VICC) received an overall “exceptional” score for its research impact and excellence in patient care. This achievement merits renewed funding from the National Cancer Institute (NCI) and places it once again in a top group of NCI Comprehensive Cancer Centers.
By Tom Wilemon
August 27, 2020

Vanderbilt-Ingram opens cancer center in Wilson County

Vanderbilt-Ingram Cancer Center at Wilson County is slated to open Aug. 31 with a full array of highly specialized services, including diagnostic assessments, medical oncology and radiation oncology.
By Tom Wilemon
May 21, 2020

State cancer plan has robust input and commitment from Vanderbilt-Ingram Cancer Center

More than a dozen representatives of Vanderbilt University Medical Center helped plan and made a commitment to help carry out the strategy for how Tennessee will prevent cancer and minimize its burden on state residents.
By Tom Wilemon
May 21, 2020

VUMC research ramps up in COVID-19 transition

As Nashville cautiously begins to emerge from its two-month-long COVID-19 Safer at Home response, so too are the labs and facilities at Vanderbilt University Medical Center.
By Bill Snyder
March 12, 2020

Triple-negative breast cancer drug therapy shows promise

Researchers from Vanderbilt-Ingram Cancer Center (VICC) discovered a role for MYCN in triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, and identified a potential intervention for further clinical investigation.
By Tom Wilemon
February 27, 2020

Breast cancer study may help predict treatment response

Researchers at VUMC are reporting another advance in the understanding and treatment of triple-negative breast cancer, which is particularly aggressive and difficult to treat.
By Bill Snyder
October 24, 2019

Pietenpol, Wilson land Komen cancer research support

Two Vanderbilt-Ingram Cancer Center investigators have received financial support from Susan G. Komen for breast cancer research.
By Tom Wilemon